TY -的T1 Bedaquiline阻力在抗药性肺结核艾滋病毒合并感染患者JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02383 -2019欧元SP - 1902383 AU -尼姆,加缪AU -米勒德,詹姆斯盟——Brien Kayleen盟——Moodley Sashen AU - van村落,露西盟——Lutchminarain Keeren盟——狼,Allison AU -格兰特,艾莉森·d . AU - Balloux,弗朗索瓦AU -宾,亚历山大·s . AU - Padayatchi Nesri AU - O ' donnell,N2 - Bedaquiline是一种高效结核病药物，是目前耐药结核病治疗方案的重要组成部分。在操作环境中，很少测试Bedaquiline抗性。在南非夸祖鲁-纳塔尔省开展的一项前瞻性队列研究中，292名耐药结核病和艾滋病患者开始服用贝他奎林，我们对92名基线培养阳性患者的分离株进行了全基因组测序。5例患者感染了携带与贝他奎林耐药相关突变的菌株，另有5例患者在治疗期间发生了获得性耐药突变。在基线培养阳性患者中，基线或获得性耐药突变的患者与未发生基线或获得性耐药突变的患者相比，临床结果明显较差。鉴于贝德奎林在当前和未来治疗中的重要性，迫切需要对贝德奎林耐药性进行常规监测，并需要加强规划，以确保充分遵守并防止耐贝德奎林结核病的广泛传播。该手稿最近已被《欧洲呼吸杂志》接受发表。在我们的制作团队进行编辑和排版之前，它以公认的形式在这里出版。当这些生产过程完成并且作者已经批准了结果证明之后，文章将转移到最新一期的在线ERJ。请打开或下载PDF阅读本文。Conflict of interest: Dr Nimmo reports grants from Wellcome Trust, during the conduct of the study.Conflict of interest: Dr Millard reports grants from Wellcome Trust, during the conduct of the study.Conflict of interest: Dr Brien has nothing to disclose.Conflict of interest: Dr Moodley has nothing to disclose.Conflict of interest: Dr van Dorp has nothing to disclose.Conflict of interest: Dr Lutchminarain has nothing to disclose.Conflict of interest: Dr Wolf reports grants from National Institutes of Health National Institute of Allergy and Infectious Diseases, during the conduct of the study.Conflict of interest: Dr Grant has nothing to disclose.Conflict of interest: Dr Balloux has nothing to disclose.Conflict of interest: Dr Pym reports personal fees from Janssen Pharmaceutica, outside the submitted work.Conflict of interest: Dr PADAYATCHI has nothing to disclose.Conflict of interest: Dr O'Donnell has nothing to disclose. ER -